Bausch + Lomb BLCO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Pharmaceuticals | $266M-16.6% | $319M+13.9% | $280M+7.7% | $260M+17.1% | $222M-17.2% | |
| Surgical | $228M-8.4% | $249M+15.8% | $215M-0.5% | $216M+0.9% | $214M-7.4% | |
| Vision Care | $711M-8.6% | $778M+5.7% | $736M-2.3% | $753M+14.8% | $656M-9.3% | |
| Operating Income (Loss) by Business | ||||||
| Pharmaceuticals | $66M-50.7% | $134M+76.3% | $76M+105% | $37M+236% | $11M-80.4% | |
| Surgical | $9M-40.0% | $15M+87.5% | $8M+300% | $2M+129% | -$7M-144% | |
| Vision Care | $202M-18.2% | $247M+13.8% | $217M+3.8% | $209M+18.8% | $176M-25.7% | |
| Selling, general and administrative (Note 4) by Business | ||||||
| Pharmaceuticals | $138M+3.8% | $133M+0.8% | $132M-14.3% | $154M+0.7% | $153M-3.2% | |
| Surgical | $73M-8.8% | $80M+11.1% | $72M-1.4% | $73M0.0% | $73M+4.3% | |
| Vision Care | $228M+2.2% | $223M-0.9% | $225M-7.4% | $243M+10.0% | $221M+6.3% | |
| R&D by Business | ||||||
| Pharmaceuticals | $22M+29.4% | $17M+13.3% | $15M+25.0% | $12M+33.3% | $9M-18.2% | |
| Surgical | $13M+44.4% | $9M-18.2% | $11M-8.3% | $12M+9.1% | $11M-15.4% | |
| Vision Care | $10M-28.6% | $14M-6.7% | $15M+36.4% | $11M+37.5% | $8M-20.0% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Pharmaceuticals | $13M+1,400% | -$1M— | $0+100% | -$71M-115% | -$33M-159% | |
| Surgical | $3M+400% | -$1M— | $0+100% | -$7M-40.0% | -$5M-171% | |
| Vision Care | $5M+350% | -$2M— | —— | -$22M-267% | -$6M-127% | |
| Goodwill by Business | ||||||
| Pharmaceuticals | $731M-1.7% | $744M+0.1% | $743M-0.7% | $748M+10.5% | $677M+5.1% | |
| Surgical | $456M-0.7% | $459M+27.1% | $361M-0.3% | $362M+2.0% | $355M+1.4% | |
| Vision Care | $3.55B-0.1% | $3.56B+0.1% | $3.55B-0.1% | $3.56B+0.6% | $3.54B+0.2% | |
| Total revenues by Product | ||||||
| Branded and Other Generics | $49M-31.0% | $71M+20.3% | $59M+1.7% | $58M+7.4% | $54M-21.7% | |
| Devices | $480M-7.3% | $518M+7.0% | $484M+2.5% | $472M+5.4% | $448M-5.9% | |
| OTC | $444M-9.4% | $490M+7.9% | $454M-5.8% | $482M+17.8% | $409M-11.5% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $1M0.0% | $1M0.0% | $1M-50.0% | $2M+100% | $1M-50.0% | |
| Product sales | $482M-9.4% | $532M+4.5% | $509M-2.7% | $523M+8.7% | $481M-3.6% | |
| Number of lawsuits pending by Geography | ||||||
| CA-BC | $1— | —— | $10.0% | $10.0% | $1— | |
| CA-QC | $1— | —— | $10.0% | $10.0% | $1— | |
| Canada | $2— | —— | $20.0% | $20.0% | $2— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch + Lomb break its business down?
- Bausch + Lomb (BLCO) reports total revenues by business across 3 parts — Pharmaceuticals, Surgical and Vision Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch + Lomb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch + Lomb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.